Phase 2 Human Immunodeficiency Virus Clinical Trials
10 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–10 of 10 trials
Recruiting
Phase 2
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting
Phase 2Phase 3
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled47 locationsNCT07266831
Recruiting
Phase 2
Baricitinib for Reduction of HIV - CNS
Human Immunodeficiency Virus
William Tyor95 enrolled2 locationsNCT05452564
Recruiting
Phase 2
Reducing Systemic Inflammation in People on Antiretroviral Therapy
Cardiovascular Risk FactorHuman Immunodeficiency Virus (HIV)
Centre hospitalier de l'Université de Montréal (CHUM)150 enrolled1 locationNCT07030920
Recruiting
Phase 2
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Merkel Cell CarcinomaMalignant NeoplasmAcquired Immunodeficiency Syndrome+5 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02479698
Recruiting
Phase 1Phase 2
Phase Ib/IIa Clinical Study of ACC017 Tablets
Infection, Human Immunodeficiency Virus
Jiangsu Aidea Pharmaceutical Group Co., Ltd.36 enrolled1 locationNCT06719310
Completed
Phase 2
An open-label study of the safety and efficacy of 12 weeks treatment with BIT225 and Combination Antiretroviral Therapy (cART) in patients with Human Immunodeficiency Virus-1 (HIV-1) with only partial immune reconstitution.
Human Immunodeficiency Virus-1 infection
Biotron Limited20 enrolled3 locationsACTRN12621001354875
Completed
Phase 2
A study of the safety and efficacy of 6 months treatment with BIT225 and Combination Antiretroviral Therapy (cART) in patients with Human Immunodeficiency Virus-1 (HIV-1) compared to cART alone, including measurement of BIT225 in the blood, antiviral activity and immune markers.
Human Immunodeficiency Virus-1 infection
Biotron Limited27 enrolled1 locationACTRN12621000937819
Completed
Phase 2
A study of the safety of 3 months treatment with BIT225 and Combination Antiretroviral Therapy (cART), in patients with Human Immunodeficiency Virus-1 (HIV-1), compared to cART alone, including measurement of the concentration of BIT225 in the blood and antiviral activity.
Human Immunodeficiency Virus-1 infection
Biotron Limited36 enrolled1 locationACTRN12617000025336
Completed
Phase 2
A study of the safety of BIT225 in combination with pegylated interferon and ribavirin in patients with hepatitis C virus and human immunodeficiency virus co-infection, who are naive to treatment with pegylated interferon and ribavirin, and whose HIV is currently well controlled by standard antiretroviral therapy.
Hepatitis C Virus infection in patients co-infected with human immunodeficiency virus-1
Biotron Limited12 enrolled1 locationACTRN12612001189819